Psylin Neurosciences Will Focus On Development of Psychiatric Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
New company is formed out of a joint venture between Amylin and PsychoGenics.
You may also be interested in...
Amylin Sees Symlin Playing “Foundational Role” In Obesity Program
CEO-to-be Bradbury outlines plans for several obesity studies of pramlintide in combination with marketed and investigational products.
Amylin Sees Symlin Playing “Foundational Role” In Obesity Program
CEO-to-be Bradbury outlines plans for several obesity studies of pramlintide in combination with marketed and investigational products.
Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs
Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: